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Abstract
Objective We investigated whether dietary carotenoid
and vitamin intake and supplemental vitamin use were
inversely associated with RCC risk and with Von Hippel-
Lindau (VHL)-gene mutations in clear-cell renal cell
carcinoma (RCC).
Methods The Netherlands Cohort Study on diet and
cancer (NLCS) includes 120,852 persons, who completed a
self-administered food-frequency questionnaire in 1986.
After 11.3 years of follow-up, 284 cases and a random
sample of 4,095 persons (subcohort) with complete data
were included in multivariable analyses using a case-cohort
approach. VHL gene mutational analysis was complete for
225 cases. Rate ratios and corresponding 95% confidence
intervals were estimated using Cox proportional hazard
models, while adjusting for age, sex, smoking, body mass
index, and a history of hypertension.
Results We observed no association for dietary caroten-
oid and vitamin intake and RCC risk, and a somewhat
increased risk with supplemental vitamin E, AD, and
multivitamin use. Results were suggestive of higher RRs
for alpha-carotene, beta-cryptoxanthin, folate, and supple-
mental vitamin C and multivitamin intake for wildtype
VHL tumors compared to VHL-mutated tumors.
Conclusions There was no association of carotenoid,
vitamin or supplemental vitamin intake and RCC risk.
These associations should be investigated by others to
confirm the current observations.
Keywords Renal cell carcinoma  Vitamins 
Carotenoids  Supplements 
von Hippel-Lindau gene mutations  Netherlands 
Cohort study
Introduction
Mutations in the von Hippel-Lindau (VHL) gene are
believed to be an early event in renal carcinogenesis.
VHL mutations are mainly observed in tumors of the
most common histological subtype, clear-cell renal cell
carcinoma (RCC) [1]. Mutations are observed in the
entire gene and usually lead to a truncated inactive
protein [1]. The VHL gene is a tumor suppressor gene
involved in cell cycle regulation, regulation of hypoxia
inducible genes and proper fibronectin assembly in
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extracellular matrix [2, 3]. It is estimated that 56–69%
[2] of clear-cell renal tumors harbor a mutation in the
VHL gene.
Occupational exposure to trichloroethylene [4, 5] and
consumption of citrus fruit and vegetables (confined to
smokers) [6] have been linked to VHL gene mutations in
RCC in previous studies [4–6]. There is some evidence
that the intake of vegetables, selenium and particularly
citrus fruit protects the renal VHL gene from mutational
insults, although chance results could not be ruled out [6].
To our knowledge, there are no other reports on an
association of fruits and vegetables, or the more specific
carotenoids and vitamin intake, and VHL gene mutations
published thus far.
Generally, intake of carotenoids and vitamins are
considered to be protective of cancer, mainly due to
their ascribed anti-oxidant capacities [7]. In a study by
Nyberg et al., diet and smoking habits were linked to
somatic mutations in vivo [8]. The mutant frequency
was significantly decreased in relation to vitamin C
intake, while a u-shaped association with higher muta-
tion frequencies at lower and higher intakes was
observed with dietary carotenoid intake [8]. Dietary
antioxidants take part in cellular reduction–oxidation
(redox) reactions in which they can act as either anti-
oxidants (electron donors) or prooxidants (electron
acceptors), depending on the physiological environment
and general oxidative state [9]. Thus, the possibility
exists that, in an environment resulting in prooxidant
activity by dietary antioxidants, antioxidant supplemen-
tation may actually cause harm in terms of increased risk
of new disease [9].
A limited number of epidemiological studies, of which
two were cohort studies, investigated the association of
carotenoids and vitamins and risk of RCC [10–21]. These
studies showed inverse or null associations but results of
these studies never consistently pointed to a null or inverse
association.
We investigated whether dietary carotenoid (alpha-
carotene, beta-carotene, lutein + zeaxanthine, beta-cryp-
toxanthine, and lycopene), and vitamin (vitamins A
(retinol), C, E, and folate) intake and supplemental vita-
min C, E, AD, and multivitamin use were associated with
sporadic RCC in a prospective cohort study. Furthermore,
we investigated the association with VHL gene mutations
in clear-cell RCC, which may explain the inconsistent
results observed in the past. Stratified analyses by
smoking were also carried out since a differential effect
by smoking status has been suggested for the association
of citrus fruits and RCC and VHL gene mutations [6], and
for the association of some carotenoids and vitamins and
RCC [14].
Subjects and methods
Netherlands Cohort Study
The Netherlands Cohort Study on diet and cancer (NLCS)
was started in September 1986. The study design has been
reported in detail elsewhere [22]. Briefly, the cohort
included 120,852 men and women aged 55–69 years in
1986. The study was designed as a case-cohort study, using
all cases and a random sample of 5,000 persons from the
cohort (subcohort), who have been followed for vital status
information to estimate the accumulated person-years in
the entire cohort [23].
Follow-up for incident cancers and vital status
The entire cohort was followed for incident cancer by
computerized record linkage with the Netherlands Cancer
Registry and PALGA, a national database of pathology
reports. All participants who reported prevalent cancer
(excluding skin cancer) at baseline were excluded from
analyses (leaving 4,774 subcohort members). The method
of record linkage to obtain information on cancer incidence
has been described previously [24]. The completeness of
cancer follow-up was estimated to be more than 96% [25].
From 1986 to 1997 (11.3 years follow up), 355 kidney
cancer cases (ICD-O-3: C64.9) were identified. Urothelial
cell carcinomas were excluded and only histologically
confirmed epithelial cancers were included (ICD-O:
M8010–8119, 8140–8570), leaving 337 cases.
The subcohort has been followed up for vital status
information biennially by mail. The vital status of subco-
hort members who did not respond, was completed by
contacting municipal population registries. Only two male
subcohort members were lost to follow-up after 11.3 years
of follow-up.
Questionnaire
At baseline, all cohort members completed a mailed, self-
administered questionnaire on dietary habits, lifestyle,
smoking, personal and family history of cancer and
demographic data [26]. The questionnaire concentrated on
the habitual consumption of food and beverages during the
year preceding the start of the study. The dietary section of
the questionnaire was a 150-item semi-quantitative food-
frequency questionnaire, which was validated against
3-day diaries completed at three time points during a
calendar year [26]. The correlation, adjusted for error
index and day-to-day variation, between the record and the
126 Cancer Causes Control (2008) 19:125–134
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questionnaire was estimated at 0.76 for vitamin A intake
and at 0.58 for vitamin C intake [26].
Mean daily nutrient intakes were calculated using the
computerized Dutch food composition table [27]. For
calculation of the intake of specific carotenoids, an addi-
tional food composition table has been constructed [28],
providing information on alpha-carotene, beta-carotene,
lutein + zeaxanthine, beta-cryptoxanthine, and lycopene.
Briefly, foods that are the main sources of carotenoids (e.g.,
vegetables) and some other foods were sampled and ana-
lyzed for alpha-carotene, beta-carotene, lutein, zeaxanthin,
and lycopene. Values for all other foods were mostly
derived from recent literature with the same methods of
analysis used. In the carotenoid food composition table,
lutein and zeaxanthin had to be taken together because
most of the literature sources did not provide separate
values for each of these carotenoids [28]. Folate data were
derived from a validated liquid chromatography trienzyme
method [29], used to analyze the 125 most important Dutch
foods contributing to folate intake [30].
Information on supplement use was collected with an
open-ended question with space for four different supple-
ments at most. Participants were asked whether they used
vitamin tablets, drops, or other preparations during the
5 years before baseline [31]. The relative validity of this
open-ended question was studied in comparison to refer-
ence information from three personal interviews carried out
within a period of 10 months [32]; recall for overall vita-
min supplement use was 72.7% [32]. In that study, vitamin
supplement use included vitamin A, C, AD, B1, B2, B6,
B12, B complex, E and multivitamin intake. In the current
study, we investigated supplemental vitamin C, E, A and/
or D (AD) and multivitamin intake.
VHL gene mutation analysis
Paraffin material of cancer cases was collected after
approval by the Medical Ethical Committees of Maastricht
University, PALGA and the Netherlands cancer registry.
We were able to collect paraffin blocks of tumors for 251
cases from 51 pathology laboratories, which we described
in detail elsewhere [33].
One experienced pathologist (CAHK) revised all HE-
stained slides. The RCC were classified according to the
World Health Organization (WHO) classification of
Tumours of 2002 [34]. DNA isolation and mutation anal-
yses have been described previously. Briefly, paraffin was
removed with xylene and DNA was extracted by salt-pre-
cipitation. The entire gene was amplified using six primer
sets. Samples were first subjected to PCR-SSCP analysis,
which was followed by direct sequencing in case of aber-
rant or equivocal results. Mutations were identified by
visual inspection of sequences provided by the ABI
basecaller. After revision and VHL gene mutation analyses,
data was available for 235 cases [33]. Information for 10
cases was discarded, since the dietary data for these sub-
jects was incomplete or inconsistent according to criteria
published before [26].
Statistical analysis
Based on the literature and previous analyses, considered
confounders were age at baseline (years), sex, body mass
index (kg/m2), a history of hypertension (yes/no), a family
history of RCC (yes/no), alcohol consumption (g/day),
social economic status (SES) based on education, non-
occupational physical activity (\30, 30–60, 60–90,
[90 min/day), occupational physical activity (for men
only) (\8, 8–12, [12 kJ/min), and energy intake (kcal/
day). Those variables that were associated with RCC and
were correlated with one of the carotenoids or vitamins
were included as covariates in multivariable analyses.
Confounders entered in these multivariable analyses were
age, sex, smoking, BMI, and a history of hypertension.
Differences in age, sex, smoking status, BMI, and a
history of hypertension between cases with (N = 225) and
without (N = 89) collected tumor material were assessed
by calculating student t-tests and chi-square tests.
RRs were calculated for the dietary intake of carotenoids
alpha-carotene, beta-carotene, lutein + zeaxanthine, beta-
cryptoxanthine and lycopene, and of the vitamins A (reti-
nol), C, E, and folate. Exposure variables were categorized
into quintiles based on the distribution in the subcohort, for
men and women separately. For vitamin C, however,
quintiles 2 and 3 and quintiles 4 and 5 were combined,
because the validation study demonstrated that these
quintiles could not be distinguished [26]. Furthermore, we
investigated use of supplemental vitamin C, E, AD and
multivitamins (yes or no).
Analyses were carried out for the following case groups
with complete data: total RCC (all cases of RCC detected
by linkage to cancer and pathology registry; N = 284);
clear-cell RCC (all cases of RCC with collected tumor
material and classified as clear-cell after revision by one
experienced pathologist (CAHK); N = 162); VHL mutated
clear-cell RCC (clear-cell RCC with a mutation in the VHL
gene; N = 97) and VHL wildtype clear-cell RCC (clear-cell
RCC without a mutation in the VHL gene; N = 65).
RRs and corresponding 95% confidence intervals (CI)
were estimated using Cox proportional hazard models
processed with STATA (STATA statistical software,
Release 7, STATA Corporation, College Station, TX,
USA, 2001), after testing the proportional hazards
assumption using scaled Schoenfeld residuals [35].
Cancer Causes Control (2008) 19:125–134 127
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Standard errors were estimated using the robust Huber-
White sandwich estimator to account for additional vari-
ance introduced by sampling from the cohort [36]. To
obtain p-values for dose–response trends, ordinal exposure
variables were fitted as continuous terms. Two sided
p-values are reported throughout this paper.
Results
Baseline characteristics for exposure variables and poten-
tial confounders for subcohort members, all cases, cases
with collected tumor material, clear-cell cases and clear-
cell cases with or without a VHL gene mutation are shown
in Table 1. First, we checked for differences in character-
istics of RCC cases for whom we could (N = 225) or could
not (N = 89) collect tumor tissue. There were no differ-
ences in mean age (p = 0.62), the percentage of men
(p = 0.16), the percentage of smokers (never, ex and cur-
rent) (p = 0.33), mean BMI (p = 0.85), or the percentage
of cases that reported a history of hypertension (p = 0.71).
We also tested differences in mean carotenoid and
vitamin intake and in the percentage of supplement users
between clear-cell RCC with and without a VHL gene
mutation. There were no remarkable differences in mean
carotenoid and vitamin intake between clear-cell RCC with
and clear-cell RCC without a VHL gene mutation (results
not shown). The percentage of supplemental vitamin C and
multivitamin users was higher for clear-cell RCC with
wildtype VHL compared to clear-cell RCC with a VHL
gene mutation. (10.1% versus 4.6 % and 10.1% (p = 0.15)
versus 3.6% (p = 0.08), respectively), although these
differences were statistically not significant.
Rate ratios for the association of carotenoids, vitamins,
and supplement use and total RCC, clear-cell RCC and
clear-cell RCC with or without VHL gene mutations are
shown in Table 2. A statistically significant inverse
association with RCC was observed in quintile 2 of
lutein + zeaxanthin intake. Furthermore, a statistically
significant increased risk of RCC was observed in quintile
4 of beta-cryptoxanthin intake. The lowest rate ratios seem
to be present in the middle quintiles (Q2–4) for carote-
noids, with the exception of beta-cryptoxanthin and
lycopene. Higher intakes of beta-cryptoxanthin and lyco-
pene were associated with an increased RCC risk. The
observed rate ratios for wildtype VHL tumors were higher
than those observed for VHL mutated tumors in case of
dietary alpha-carotene and beta-cryptoxanthin intake
(Table 2). Vitamin intake did not seem to be associated
with RCC risk, but there was a possible differential effect
for folate intake between tumors with and without a VHL
gene mutation. Rate ratios were mostly greater than 1 in
case of wildtype VHL tumors, while these were mostly
lower than 1 for VHL mutated tumors. Supplemental
vitamin E, AD and multivitamin use were associated with
increased RCC risk, while there was no association of
supplemental vitamin C use and RCC risk. Stratified
analyses based on VHL mutational status revealed higher
RRs for wildtype tumors in case of supplemental vitamin C
and multivitamin use and lower RRs for wildtype tumors in
case of supplemental vitamin E and AD use. Supplemental
multivitamin use was associated with a statistically sig-
nificant increased risk of clear-cell tumors without a VHL
gene mutation (RR: 2.51; 95% CI: 1.10–5.75).
We also investigated possible interaction by sex and
cigarette smoking status. Although we observed a statisti-
cally significant interaction of sex and beta-carotene intake
for RCC (p = 0.03), stratified analyses showed that there
was no consistent differential effect for sex over the
quintiles (results not shown). P-values for interaction by
smoking (never, ex and current smokers) ranged from 0.17
for folate to 0.85 for supplemental vitamin E use in mul-
tivariable analyses. We repeated these analyses for the
subgroups of clear-cell cases with or without a VHL gene
mutation. No conclusions could be drawn based on these
results since the low number of cases, especially in the
supplemental vitamin use groups, hampered analyses
(results not shown).
Discussion
We investigated the association of several dietary carote-
noids and vitamins (A, C, E, and folate) and supplemental
vitamin C, E, AD and multivitamin use and RCC incidence
in the NLCS. We observed no association for carotenoids
and vitamins from diet and RCC risk. This is not surpris-
ing, since we also observed null associations for vegetable
and fruit consumption and RCC risk [37]. Contrary to
expectations, we observed a small statistically non-signif-
icant increased risk with supplemental vitamin E, AD, and
multivitamin use.
Important strengths from the NLCS are that exposure
was assessed before the diagnosis of cancer and that only
incident cases were included. Therefore, recall bias is not
likely to have influenced our results. Furthermore, selection
bias is also unlikely because of the high completeness of
follow-up of cases and subcohort members.
The consumption of vegetables and fruits, which con-
tribute the most to the intake of carotenoids and vitamins,
was extensively measured in the NLCS, using a validated
semi-quantitative food-frequency questionnaire. In a
reproducibility study, it was further demonstrated that the
single food frequency questionnaire measurement could
characterize dietary habits for a period of at least 5 years
[38]. Misclassification of exposure may have occurred.
128 Cancer Causes Control (2008) 19:125–134
123
T
a
b
le
1
D
es
cr
ip
ti
v
es
fo
r
ca
ro
te
n
o
id
s,
v
it
am
in
s,
su
p
p
le
m
en
t
u
se
an
d
co
n
fo
u
n
d
in
g
fa
ct
o
rs
fo
r
su
b
co
h
o
rt
m
em
b
er
s
an
d
ca
se
g
ro
u
p
s.
N
L
C
S
1
9
8
6
–
1
9
9
7
S
u
b
co
h
o
rt
R
C
C
to
ta
l
T
u
m
o
r
m
at
er
ia
l
co
ll
ec
te
d
C
le
ar
-c
el
l
R
C
C
C
le
ar
-c
el
l
R
C
C
V
H
L
m
u
ta
te
d
C
le
ar
-c
el
l
R
C
C
V
H
L
w
il
d
ty
p
e
N
=
4
4
3
8
N
=
3
1
4
N
=
2
2
5
N
=
1
7
9
N
=
1
1
0
N
=
6
9
C
a
ro
te
n
o
id
s
A
lp
h
a-
ca
ro
te
n
e
(m
g
/d
ay
)
M
ea
n
(S
D
)
0
.6
9
6
(0
.5
6
9
)
0
.6
8
5
(0
.4
9
5
)
0
.6
6
6
(0
.4
4
4
)
0
.6
7
6
(0
.4
6
2
)
0
.6
7
4
(0
.4
7
8
)
0
.6
8
0
(0
.4
3
9
)
B
et
a-
ca
ro
te
n
e
(m
g
/d
ay
)
M
ea
n
(S
D
)
2
.9
6
(1
.5
7
)
2
.9
7
(1
.4
4
)
2
.9
1
(1
.2
4
)
2
.9
4
(1
.3
1
)
2
.9
4
(1
.3
6
)
2
.9
3
(1
.2
5
)
L
u
te
in
+
Z
ea
x
an
th
in
(m
g
/d
ay
)
M
ea
n
(S
D
)
2
.5
0
(1
.1
3
)
2
.5
6
(1
.1
1
)
2
.5
0
(1
.0
3
)
2
.5
2
(1
.0
6
)
2
.5
7
(1
.1
1
)
2
.4
4
(0
.9
9
1
)
B
et
a-
cr
y
p
to
x
an
th
in
(m
g
/d
ay
)
M
ea
n
(S
D
)
0
.1
7
9
(0
.1
7
9
)
0
.1
8
6
(0
.1
7
9
)
0
.1
8
5
(0
.1
7
2
)
0
.1
8
8
(0
.1
6
8
)
0
.1
8
6
(0
.1
6
8
)
0
.1
9
1
(0
.1
6
9
)
L
y
co
p
en
e
(m
g
/d
ay
)
M
ea
n
(S
D
)
1
.2
0
(1
.7
7
)
1
.1
8
(1
.8
8
)
1
.2
6
(2
.1
5
)
1
.2
5
(2
.2
1
)
1
.1
3
(1
.2
8
)
1
.4
5
(3
.1
7
)
D
ie
ta
ry
vi
ta
m
in
s
V
it
am
in
A
(r
et
in
o
l)
(m
g
/d
ay
)
M
ea
n
(S
D
)
0
.9
7
0
(0
.4
1
8
)
0
.9
7
7
(0
.4
2
9
)
0
.9
6
7
(0
.4
2
8
)
0
.9
7
7
(0
.4
5
3
)
0
.9
8
1
(0
.4
5
5
)
0
.9
7
1
(0
.4
5
4
)
V
it
am
in
C
(m
g
/d
ay
)
M
ea
n
(S
D
)
1
0
3
(4
3
.8
)
1
0
3
(4
4
.8
)
1
0
2
(4
3
.8
)
1
0
2
(4
3
.6
)
1
0
1
(4
1
.9
)
1
0
3
(4
6
.6
)
V
it
am
in
E
(m
g
/d
ay
)
M
ea
n
(S
D
)
1
3
.4
(6
.1
9
)
1
3
.9
(6
.8
1
)
1
3
.6
(6
.1
4
)
1
3
.6
(6
.2
9
)
1
3
.4
(6
.4
4
)
1
3
.8
(6
.0
9
)
F
o
la
te
(m
g
/d
ay
)
M
ea
n
(S
D
)
0
.2
1
1
(0
.0
7
2
2
)
0
.2
1
4
(0
.0
7
7
1
)
0
.2
1
1
(0
.0
7
5
5
)
0
.2
1
1
(0
.0
7
8
0
)
0
.2
0
8
(0
.0
7
1
2
)
0
.2
1
5
(0
.0
8
8
1
)
V
it
a
m
in
su
p
p
le
m
en
ts
S
u
p
p
le
m
en
ta
l
v
it
am
in
C
u
se
r
=
y
es
N
(%
)
2
8
9
(6
.5
)
1
9
(6
.1
)
1
5
(6
.7
)
1
2
(6
.7
)
5
(4
.6
)
7
(1
0
.1
)
S
u
p
p
le
m
en
ta
l
v
it
am
in
E
u
se
r
=
y
es
N
(%
)
8
7
(2
.0
)
9
(2
.9
)
5
(2
.2
)
4
(2
.2
)
3
(2
.7
)
1
(1
.5
)
S
u
p
p
le
m
en
ta
l
v
it
am
in
A
D
u
se
r
=
y
es
N
(%
)
1
3
0
(2
.9
)
1
1
(3
.5
)
6
(2
.7
)
5
(2
.8
)
3
(2
.7
)
2
(2
.9
)
S
u
p
p
le
m
en
ta
l
m
u
lt
iv
it
am
in
u
se
=
y
es
N
(%
)
2
0
7
(4
.7
)
2
1
(6
.7
)
1
6
(7
.1
)
1
1
(6
.2
)
4
(3
.6
)
7
(1
0
.1
)
C
o
n
fo
u
n
d
in
g
fa
ct
o
rs
A
g
e
M
ea
n
(S
D
)
6
1
.4
(4
.2
3
)
6
1
.9
(3
.8
8
)
6
2
.0
(3
.8
7
)
6
1
.7
(3
.8
2
)
6
1
.8
(3
.7
6
)
6
1
.5
(3
.9
2
)
S
ex
=
m
al
e
N
(%
)
2
1
9
1
(4
9
.4
)
2
0
7
(6
5
.9
)
1
4
3
(6
3
.6
)
1
0
8
(6
0
.3
)
6
9
(6
2
.7
)
3
9
(5
6
.5
)
C
ig
a
re
tt
e
sm
o
ke
r
N
ev
er
N
(%
)
1
5
9
0
(3
5
.8
)
7
8
(2
4
.8
)
5
8
(2
5
.8
)
4
7
(2
6
.3
)
3
1
(2
8
.2
)
1
6
(2
3
.2
)
E
x
N
(%
)
1
5
9
3
(3
5
.9
)
1
2
2
(3
8
.9
)
9
1
(4
0
.4
)
7
4
(4
1
.3
)
4
7
(4
2
.7
)
2
7
(3
9
.1
)
C
u
rr
en
t
N
(%
)
1
2
5
5
(2
8
.3
)
1
1
4
(3
6
.3
)
7
6
(3
3
.8
)
5
8
(3
2
.4
)
3
2
(2
9
.1
)
2
6
(3
7
.7
)
C
ig
ar
et
te
s
sm
o
k
ed
p
er
d
ay
M
ea
n
(S
D
)
9
.5
1
(1
0
.9
)
1
3
.1
(1
3
.1
)
1
3
.3
(1
3
.4
)
1
3
.7
(1
3
.9
)
1
3
.6
(1
3
.4
)
1
3
.8
(1
4
.8
)
N
u
m
b
er
in
an
al
y
se
s*
N
=
4
2
7
2
N
=
2
9
3
N
=
2
0
9
N
=
1
6
8
N
=
1
0
2
N
=
6
6
Y
ea
rs
o
f
ci
g
ar
et
te
sm
o
k
in
g
M
ea
n
(S
D
)
2
0
.2
(1
8
.2
)
2
5
.5
(1
8
.2
)
2
4
.8
(1
8
.1
)
2
4
.2
(1
8
.0
)
2
3
.6
(1
8
.0
)
2
5
.2
(1
7
.9
)
N
u
m
b
er
in
an
al
y
se
s*
N
=
4
3
8
0
N
=
3
1
0
N
=
2
2
3
N
=
1
7
7
N
=
1
0
9
N
=
6
8
K
id
n
ey
ca
n
ce
r
in
fi
rs
t-
d
eg
re
e
re
la
ti
v
es
=
y
es
N
(%
)
4
3
(1
.0
)
3
(1
.0
)
3
(1
.3
)
2
(1
.1
)
2
(1
.8
)
0
B
M
I
M
ea
n
(S
D
)
2
5
.0
(3
.1
2
)
2
5
.5
(2
.9
5
)
2
5
.5
(2
.8
9
)
2
5
.8
(3
.0
0
)
2
5
.8
(3
.0
5
)
2
5
.8
(2
.9
3
)
N
u
m
b
er
in
an
al
y
se
s*
N
=
4
2
9
2
N
=
3
0
4
N
=
2
1
5
N
=
1
7
2
N
=
1
0
4
N
=
6
8
H
is
to
ry
o
f
h
y
p
er
te
n
si
o
n
=
y
es
N
(%
)
1
1
5
6
(2
6
.1
)
9
4
(2
9
.9
)
6
6
(2
9
.3
)
5
2
(2
9
.1
)
3
5
(3
1
.8
)
1
7
(2
4
.6
)
*
T
h
e
n
u
m
b
er
o
f
ca
se
s
w
as
lo
w
er
in
an
al
y
se
s
fo
r
n
u
m
b
er
o
f
ci
g
ar
et
te
s
sm
o
k
ed
p
er
d
ay
,
n
u
m
b
er
o
f
y
ea
rs
o
f
ci
g
ar
et
te
sm
o
k
in
g
,
an
d
B
M
I
d
u
e
to
m
is
si
n
g
v
al
u
es
Cancer Causes Control (2008) 19:125–134 129
123
Table 2 Relative risks for the association of dietary carotenoid and vitamin intake, and supplemental vitamin use and Renal Cell Carcinoma
(RCC), clear-cell RCC and clear-cell RCC with or without a von Hippel-Lindau gene mutation, NLCS 1986–1997
Carotenoid/vitamin Median intake
in subcohort
RCC Clear-cell RCC Clear-cell RCC
VHL gene mutated
Clear-cell RCC
wildtype
Men/women RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Number of cases 284 162 97 65
Number person-years in subcohort 42972 42972 42972 42972
Alpha-carotene
Q1 0.19/0.18 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 0.38/0.37 0.85 (0.59–1.24) 0.81 (0.49–1.34) 0.67 (0.35–1.28) 1.07 (0.48–2.38)
Q3 0.57/0.56 0.82 (0.56–1.20) 0.97 (0.60–1.57) 0.93 (0.51–1.68) 1.04 (0.47–2.32)
Q4 0.82/0.82 0.76 (0.52–1.12) 0.76 (0.45–1.26) 0.61 (0.31–1.17) 1.05 (0.47–2.34)
Q5 1.31/1.32 0.90 (0.62–1.31) 0.96 (0.59–1.57) 0.84 (0.45–1.55) 1.20 (0.54–2.65)
P-trend 0.46 0.80 0.53 0.71
Continuous per 0.1 mg/day 0.99 (0.97–1.01) 0.98 (0.96–1.01) 0.98 (0.95–1.02) 0.99 (0.95–1.03)
Beta-carotene
Q1 1.48/1.39 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 2.14/2.03 0.76 (0.51–1.12) 0.92 (0.54–1.55) 0.89 (0.45–1.74) 0.96 (0.43–2.17)
Q3 2.67/2.61 0.84 (0.57–1.23) 1.22 (0.74–2.01) 1.26 (0.67–2.36) 1.17 (0.53–2.56)
Q4 3.37/3.32 0.84 (0.57–1.23) 1.01 (0.61–1.69) 1.09 (0.58–2.07) 0.89 (0.39–2.04)
Q5 4.75/4.72 0.97 (0.67–1.40) 1.09 (0.66–1.82) 0.94 (0.48–1.83) 1.34 (0.62–2.89)
P-trend 0.95 0.64 0.92 0.54
Continuous per 1 mg/day 0.98 (0.91–1.06) 0.96 (0.87–1.05) 0.95 (0.84–1.07) 0.98 (0.85–1.12)
Lutein + Zeaxanthin
Q1 1.42/1.30 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 1.89/1.81 0.66 (0.45–0.99) 0.68 (0.41–1.13) 0.57 (0.28–1.14) 0.84 (0.40–1.79)
Q3 2.37/2.29 0.79 (0.54–1.16) 0.81 (0.49–1.31) 0.78 (0.41–1.46) 0.85 (0.40–1.79)
Q4 2.86/2.78 0.92 (0.64–1.33) 0.99 (0.62–1.58) 1.12 (0.63–2.02) 0.79 (0.37–1.68)
Q5 3.89/3.77 0.90 (0.62–1.29) 0.76 (0.46–1.25) 0.76 (0.40–1.45) 0.76 (0.35–1.63)
P-trend 0.88 0.74 0.89 0.48
Continuous per 1 mg/day 1.01 (0.91–1.12) 0.96 (0.84–1.10) 0.98 (0.81–1.17) 0.94 (0.76–1.15)
Beta-cryptoxanthin
Q1 0.01/0.03 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 0.04/0.09 1.08 (0.72–1.62) 1.24 (0.72–2.13) 1.00 (0.52–1.93) 1.88 (0.73–4.82)
Q3 0.10/0.17 0.99 (0.65–1.50) 1.11 (0.64–1.93) 0.63 (0.30–1.32) 2.40 (0.97–5.95)
Q4 0.20/0.27 1.56 (1.06–2.28) 1.58 (0.95–2.65) 1.18 (0.63–2.22) 2.64 (1.08–6.46)
Q5 0.36/0.50 1.17 (0.78–1.74) 1.40 (0.83–2.36) 1.30 (0.70–2.42) 1.61 (0.62–4.16)
P-trend 0.11 0.11 0.31 0.18
Continuous per 0.05 mg/day 1.03 (1.00–1.06) 1.03 (0.99–1.07) 1.03 (0.98–1.08) 1.03 (0.97–1.09)
Lycopene
Q1 0.14/0.17 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 0.42/0.56 0.90 (0.59–1.35) 0.68 (0.38–1.21) 0.81 (0.41–1.63) 0.45 (0.16–1.29)
Q3 0.74/0.90 1.12 (0.76–1.67) 1.21 (0.73–2.00) 1.10 (0.58–2.09) 1.40 (0.64–3.06)
Q4 1.11/1.30 1.35 (0.93–1.98) 1.47 (0.90–2.38) 1.26 (0.68–2.36) 1.81 (0.86–3.82)
Q5 1.98/2.33 1.17 (0.79–1.72) 1.23 (0.74–2.04) 1.13 (0.59–2.16) 1.39 (0.64–3.05)
P-trend 0.10 0.05 0.36 0.04
Continuous per 0.5 mg/day 1.01 (0.88–1.17) 1.05 (0.88–1.25) 0.96 (0.79–1.18) 1.13 (0.89–1.44)
Vitamin A (retinol)
Q1 0.61/0.52 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 0.81/0.70 1.01 (0.69–1.48) 0.96 (0.58–1.60) 1.11 (0.59–2.10) 0.76 (0.34–1.72)
Q3 0.95/0.84 1.00 (0.68–1.47) 1.12 (0.69–1.84) 1.14 (0.60–2.14) 1.11 (0.52–2.36)
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However, from our validation study it was concluded that
the questionnaire could satisfactorily rank subjects
according to the intake of vitamins [26]. Carotenoids could
not be assessed in this validation study because the food
composition tables for carotenoids were not available at
that time. However, for vegetable and fruit consumption,
associations have been observed with lung [39] and colo-
rectal [40] cancer within the NLCS. Since vegetables are
the main source of carotenoids (with the exception of beta-
cryptoxanthin), these results show that the validity
appeared to be sufficient to detect associations. However,
this was less clear for previous studies on carotenoids and
vitamins within the NLCS [41–44]. If misclassification has
occurred, we expect this to be nondifferential and risk
estimates are most likely biased towards the null value.
This may explain our negative results. The assessment of
intake of vitamin supplements was also shown to be rea-
sonably good in our study [32].
We cannot exclude the possibility that residual con-
founding has influenced our results, even though we tried
Table 2 continued
Carotenoid/vitamin Median intake
in subcohort
RCC Clear-cell RCC Clear-cell RCC
VHL gene mutated
Clear-cell RCC
wildtype
Men/women RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Q4 1.14/1.01 0.73 (0.48–1.11) 0.75 (0.44–1.29) 0.89 (0.45–1.75) 0.57 (0.23–1.37)
Q5 1.51/1.37 1.13 (0.78–1.64) 1.05 (0.64–1.72) 0.94 (0.49–1.81) 1.20 (0.58–2.48)
P-trend 0.96 0.84 0.63 0.81
Continuous per 0.1 mg/day 0.99 (0.96–1.03) 1.00 (0.95–1.04) 1.00 (0.94–1.05) 1.00 (0.94–1.06)
Vitamin C
Q1 52.23/58.93 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 + Q3 81.78/92.73 1.10 (0.78–1.55) 1.04 (0.67–1.60) 0.90 (0.52–1.56) 1.28 (0.65–2.55)
Q4 + Q5 129.76/140.84 1.01 (0.72–1.43) 0.88 (0.57–1.38) 0.87 (0.50–1.50) 0.91 (0.44–1.87)
P-trend 0.99 0.48 0.63 0.58
Continuous per 10 mg/day 1.01 (0.98–1.04) 0.99 (0.96–1.03) 0.99 (0.94–1.04) 1.00 (0.94–1.06)
Vitamin E
Q1 7.18/6.13 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 10.56/8.54 0.77 (0.51–1.16) 0.66 (0.38–1.15) 0.91 (0.46–1.78) 0.35 (0.12–0.97)
Q3 13.54/11.05 1.09 (0.75–1.58) 1.16 (0.72–1.88) 1.53 (0.84–2.80) 0.69 (0.30–1.57)
Q4 17.20/14.40 1.04 (0.72–1.52) 1.13 (0.70–1.81) 0.74 (0.37–1.49) 1.63 (0.85–3.13)
Q5 23.76/19.55 1.00 (0.68–1.47) 0.90 (0.54–1.50) 1.00 (0.52–1.93) 0.76 (0.34–1.70)
P-trend 0.53 0.63 0.81 0.30
Continuous per 5 mg/day 1.05 (0.95–1.15) 1.03 (0.90–1.16) 1.00 (0.84–1.19) 1.07 (0.89–1.27)
Folate
Q1 0.15/0.13 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 0.18/0.16 0.83 (0.56–1.24) 0.74 (0.44–1.24) 0.62 (0.33–1.19) 0.99 (0.42–2.34)
Q3 0.21/0.19 1.04 (0.72–1.52) 1.08 (0.74–1.77) 1.02 (0.58–1.80) 1.20 (0.54–2.66)
Q4 0.25/0.22 0.86 (0.58–1.27) 0.81 (0.49–1.35) 0.52 (0.26–1.05) 1.44 (0.66–3.14)
Q5 0.31/0.27 0.95 (0.65–1.40) 0.79 (0.48–1.31) 0.65 (0.34–1.23) 1.10 (0.49–2.48)
P-trend 0.88 0.50 0.17 0.52
Continuous per 0.1 mg/day 0.99 (0.83–1.19) 0.95 (0.73–1.23) 0.88 (0.62–1.23) 1.05 (0.71–1.53)
Supplement use Exposed (%)*
No 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Supplemental vitamin C user = yes 6.6/6.3/6.8/4.1/10.8 0.95 (0.57–1.58) 1.07 (0.57–2.02) 0.64 (0.23–1.75) 1.76 (0.79–3.95)
Supplemental vitamin E user = yes 2.0/3.2/2.5/3.1/1.5 1.83 (0.89–3.78) 1.42 (0.50–4.01) 1.92 (0.59–6.31) 0.81 (0.11–6.07)
Supplemental vitamin AD user = yes 2.9/3.9/3.1/3.1/3.1 1.42 (0.74–2.73) 1.04 (0.41–2.67) 1.12 (0.33–3.74) 0.95 (0.22–5.75)
Supplemental multivitamin use = yes 4.7/6.3/6.2/3.1/10.8 1.51 (0.91–2.51) 1.43 (0.73–2.79) 0.72 (0.22–2.28) 2.51 (1.10–5.75)
All models adjusted for age, sex, smoking (current smoker yes or no; number of cigarettes per day; number of smoking years), BMI and history
of hypertension
Supplemental vitamin C, E, AD and multivitamin use are in one model. *Percentage exposed: subcohort/RCC/clear-cell RCC/clear-cell RCC
VHL gene mutated/clear-cell RCC wildtype
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to investigate and adjust for the appropriate confounding
factors. All possible confounding factors as reported from
the literature and measured within the cohort were included
in the analyses if associated with RCC risk and correlated
with at least one of the exposure factors in our population.
Chance may have played a role since a large number of
associations was tested, but we hardly observed statistically
significant associations.
Finally, power may have been a problem since the
number of cases in subgroup analyses was sometimes low,
although results across quintiles did not point in the
direction of a dose–response relationship. This prospective
cohort study, the third to report on carotenoids, vitamins
and supplement intake, was based on 314 incident RCC
cases after 11.3 years of follow-up (284 cases with com-
plete data in multivariable analyses). The Iowa Women’s
Health Study [10] was the first cohort study to report on
carotenoids, vitamins and supplement use, analyzing 124
incident cases after 15 years of follow-up. Recently, a
report on the Nursus Health Study and the Health Profes-
sionals study with results on 132 women and 116 men,
respectively, was published [11].
For carotenoids, there was an indication for a u-shaped
association with RCC. This was less clear in the case
groups of clear-cell RCC, and clear-cell RCC with or
without a VHL gene mutation, possibly because of the
smaller number of cases. This observation is in line with
the observation of a u-shaped association with higher
mutation frequencies at lower and higher intakes of dietary
carotenoid intake [8]. Despite these suggestive results, we
only observed a statistically significant inverse association
in quintile 2 of lutein + zeaxanthin intake. For lycopene
and beta-cryptoxanthin, risks seemed to be increased,
without an indication of a u-shaped association. Lycopene
is mainly derived from tomatoes, and citrus fruits including
mandarins are an important source of beta-cryptoxanthin.
Both tomato consumption and mandarin consumption were
associated with a increased RCC risk in our population
[37]. We could not explain the previously observed results
for tomato and mandarin consumption and ascribed them to
chance. Most results for carotenoids were not statistically
significant, leading us to conclude that there was no asso-
ciation with RCC risk.
These results are in line with most other studies, which
reported statistically non-significant inverse and null
associations [10, 14, 18–20]. Two studies reported statis-
tically significant inverse associations. A large population
based case-control study including 1,204 cases found a
statistically significant inverse association for alpha-caro-
tene, beta-carotene, lutein, and beta-cryptoxanthin [13]. A
recent cohort study found that individual carotenoids
except lycopene were significantly associated with a lower
risk of renal cell cancer in men only [11].
We observed no association of dietary vitamin intake
and RCC risk. A statistically non-significant inverse asso-
ciation has been found for folate [20]. For vitamins A and
E, mostly null associations and non-statistically significant
inverse associations have been reported [10, 11, 13, 14, 19,
20], although in one study a statistically significant inverse
association with vitamin E intake was found [20]. For
vitamin C intake, reported associations were mostly not
statistically significant, but generally somewhat more
suggestive of a possible protective effect [10, 11, 13, 14,
18, 20].
Supplemental vitamin E and multivitamin use seemed to
be associated with an increased RCC risk (not statistically
significant). One trial on vitamin supplementation and RCC
risk was carried out (the ATBC study [21]). In this trial,
smokers were randomly assigned to supplemental alpha-
tocopherol, beta-carotene, alpha-tocopherol and beta-car-
otene, or a placebo. No statistically significant differences
in incidence/mortality rates of RCC were observed [21].
However, an inverse association was observed with mul-
tivitamin supplement use in the Iowa women’s health study
(RR: 0.63; 95% CI: 0.42, 0.93) [10]. Two other large
population-based case-control studies reported a null
association with supplement use [13, 14].
We also investigated possible effect-modification by
smoking. We did not observe a differential effect for never,
ex and current smokers. Thus far, stronger inverse associ-
ation for non-smokers [14] as well as non-differential
effects [13] has been published. In the study by Hemminki
et al. [6], it was noted that smoking appeared to change the
outcome of many variables (although smoking itself was
not a risk factor for VHL gene mutations). However, small
numbers in that study did not allow for testing of smoking
as a true effect modifier. In the current study, numbers were
also too small to draw firm conclusions from interaction
tests and from analyses stratified by smoking.
We were able to investigate risk factors for the specific
histological subtype clear-cell RCC and also for the pres-
ence of VHL gene mutations, which has not been done
before for vitamins and carotenoids. There has only been
one report on diet and VHL gene mutations based on a
case-only analysis [6]. The authors of that study concluded
that their results provide evidence that the intake of veg-
etables, selenium and particularly citrus fruit protects the
renal VHL gene from mutational insults, although chance
results could not be ruled out in that relatively small study
[6]. Based on case-only comparisons, we would have
observed a non-statistically significant protective effect of
supplemental multivitamin intake on VHL gene mutations
(OR = 0.22; 95% CI: 0.05, 1.02). However, compared to
the subcohort, the risk for wildtype VHL tumors was
increased (RR = 2.51; 95% CI: 1.10–5.75) which shows
that case-only comparisons can be misleading. Thus, we
132 Cancer Causes Control (2008) 19:125–134
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observed an increased risk for VHL wildtype clear-cell
tumors for supplement use and not a protective effect of
supplemental multivitamin use on VHL gene mutations.
In summary, no statistically significant dose–response
associations were observed. Stratified results by VHL gene
mutation showed no statistically significant differential
effects, although results were sometimes suggestive of a
differential effect. These associations should be investi-
gated by others to confirm the current observations.
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